Pharmaceutical Giant Expands Cancer Portfolio
Eli Lilly is nearing a deal to acquire Kelonia Therapeutics, a cancer biotech company, for over $2 billion. The acquisition, which could be finalized as soon as Monday, is part of Eli Lilly’s efforts to expand its cancer treatment portfolio. According to people familiar with the matter, the deal price may include additional consideration if Kelonia reaches certain milestones. This development was reported by The Wall Street Journal.
Pharmaceutical Giant Expands Cancer Portfolio
Eli Lilly is nearing a deal to acquire Kelonia Therapeutics, a cancer biotech company, for over $2 billion. The acquisition, which could be finalized as soon as Monday, is part of Eli Lilly’s efforts to expand its cancer treatment portfolio. According to people familiar with the matter, the deal price may include additional consideration if Kelonia reaches certain milestones. This development was reported by The Wall Street Journal.